The effectiveness and safety of extracorporeal shock wave lithotripsy for the management of kidney stones
A protocol of systematic review and meta-analysis
Yong-chun Qiang, MBa, Yu-ge Guo, MBb, Yun-qi Wang, MMc,∗

Abstract
Background: This study will assess the effectiveness and safety of extracorporeal shock wave lithotripsy (ESWL) for patients with kidney stones (KS).
Methods: A comprehensive and systematic literature records search for studies will be conducted in MEDLINE, EMBASE, Cochrane Library, WANGFANG, VIP, Chinese Biomedical Literature Database, and China National Knowledge Infrastructure. All these databases will be searched from inception to the present without language limitation. Cochrane risk of bias tool will be used to assess the methodological quality for all included studies. Statistical analysis is performed using RevMan 5.3 software.
Results: This study will provide synthesis of current evidence of ESWL for patients with KS through assessing primary outcomes of overall stone-free rate, and secondary outcomes of mean stone size (mm), pain intensity, urinary biochemical variables, mean hospital stay (day), quality of life, and adverse events.
Conclusion: This study will provide recommendations for the effectiveness and safety of ESWL for patients with KS, which may help to guide clinician.

PROSPERO registration number: PROSPERO CRD42019157243.
Abbreviations: CIs = confidence intervals, ESWL = extracorporeal shock wave lithotripsy, KS = kidney stones, RCTs = randomized controlled trials.
Keywords: effectiveness, extracorporeal shock wave lithotripsy, kidney stones, safety

1. Introduction
Kidney stones (KS), also known as nephrolithiasis, is a very common urological disease.1–4 It has been estimated that its prevalence rates are up to 14.8% and increasing, and its recurrence rates are up to 50% within the subsequent 5 to 10 years after the first episode.5,6 If it cannot be treated effectively, it can cause significant morbidity, and can seriously impact quality of life in patients with KS.7–9 Risk factors including obesity, diabetes mellitus, hypertension and metabolic syndrome contribute to the KS formation.10–13 A variety of managements for KS are available, such as acupuncture, herbal medicine, surgery, dietary supplementation, oral medicine, and extracorporeal shock wave lithotripsy (ESWL).14–21 A numerous studies have reported that ESWL can effectively treat patients with KS.22–32 Although a previous related systematic review has been conducted in 2014,24 there still several high quality clinical trials have been published after that.25–32 Therefore, this update study will investigate the effectiveness and safety of ESWL for the treatment of KS.

2. Methods

2.1. Study registration
We have registered this study on PROSPERO (CRD42019157243). It has been reported following the guidelines of Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols Statement.33

2.2. Eligibility criteria
2.2.1. Type of studies. We will include randomized controlled trials (RCTs) that focused on the ESWL for patients with KS without language and publication status limitations. However, non-RCTs, and quasi-RCTs will not be included.

This study has supported by the Yan’an Science and Technology Huimin Project (2016-HM-08-01). The funder had no role in this study.
The authors have no conflicts of interest to disclose.
YQ and YG contributed equally to this work.
Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.
* Department of Urology, Xianyang Hospital of Yan’an University, 2 Department of Obstetrics and Gynecology, 3 Department of Urology, Yangling Demonstration District Hospital, Xianyang, China.
* Correspondence: Yun-qi Wang, Department of Urology, Yangling Demonstration District Hospital, No.8 Houji Road, Yangling District, Xianyang 712100, China (e-mail: Yun-qiwang3108@outlook.com).
Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc.
This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
How to cite this article: Qiang Yc, Guo Yg, Wang Yq. The effectiveness and safety of extracorporeal shock wave lithotripsy for the management of kidney stones: A protocol of systematic review and meta-analysis. Medicine 2020;99:19 (e19915).
Received: 14 March 2020 / Accepted: 18 March 2020
http://dx.doi.org/10.1097/MD.00000000000019915
2.2.2. Type of participants. All included participants must be diagnosed with KS, regardless of country, ethnic background, gender, age, and economic status.

2.2.3. Type of interventions. Any forms of ESWL intervention alone has been assigned to the patients in the experimental group. The intervention in the control group could be any management, except the ESWL.

2.2.4. Type of outcomes. The primary outcomes is overall stone-free rate. The secondary outcomes are mean stone size (mm), pain intensity, urinary biochemical variables, mean hospital stay (day), quality of life, and adverse events.

2.3. Search strategy

We will search the following electronic bibliographic databases comprehensively and systematically from their inception to the present: MEDLINE, EMBASE, Cochrane Library, WANG-FANG, VIP, Chinese Biomedical Literature Database, and China National Knowledge Infrastructure. All databases will be searched without language limitation. The search keywords include kidney stones, renal lithiasis, nephrolithiasis, extracorporeal shock wave lithotripsy, ESWL, shock waves, random, randomly, controlled trial, clinical trial, blind, control, comparator, allocation, and concealment. The detailed search strategy for MEDLINE is demonstrated in Table 1. Similar search strategies will be built for other electronic databases.

Additionally, we will also search gray literature sources, such as conference proceedings, dissertations, clinical trial registry, and reference lists of included studies.

2.4. Data selection and extraction

2.4.1. Study selection. Two researchers are independently responsible for the study selection based on the previously defined study inclusion criteria. All retrieved studies will be scanned in the forms of titles and abstracts initially, and all unqualified and duplicated studies will be removed. Then, we will read full texts of the remaining studies for further selection. All excluded literatures will be recorded separately with detailed reasons. In case of any different opinions between two researchers, a third researcher will help to make decision through negotiation. The process of study selection will be presented in the flowchart in Figure 1.

2.4.2. Data extraction. The following information will be independently extracted by two researchers through pre-designed standard sheet: first author, publication year, location, race, age, sex, disease duration and duration, diagnostic criteria, eligibility criteria, sample size, study setting, methods of randomization, blind, concealment, treatment details, all outcome measurements, safety, and funding information. We will contact primary authors by email if essential information is missing or unclear. A third researcher will help to solve any disagreements between two researchers by discussion if necessary.

2.5. Study quality assessment

Two researchers will evaluate the risk of bias for all included RCTs using Cochrane Risk of Bias Tool. We will assess each study at 7 levels, and each one is divided into 3 degrees: low, unclear, and high risk of bias. The differences between two researchers will be solved by consensus via discussion.

2.6. Data analysis

RevMan 5.3 software is utilized for statistical analysis. All continuous data will be calculated as mean difference or standardized mean difference and 95% confidence intervals (CIs), while all dichotomous will be calculated as risk ratio and 95% CIs. Statistical heterogeneity across the eligible studies will be checked by $I^2$ statistic. $I^2 ≤ 50\%$ indicates low level of heterogeneity, and we will choose a fixed-effects model. $I^2 > 50\%$ means obvious level of heterogeneity, and we will select a random-effects model. When the heterogeneity of the merged outcome results across studies is low, we will plan to perform a meta-analysis if more than two RCTs are similar in study and patient characteristics, interventions, controls, and outcomes. In contrast, we will perform a subgroup analysis to check possible reasons for the obvious heterogeneity. We will not conduct a meta-analysis if obvious heterogeneity still be checked after subgroup analysis. Instead, we will report outcome results as a narrative summary.

2.7. Subgroup analysis

When there is obvious heterogeneity among included studies, we will perform a subgroup analysis in accordance with different study qualities, treatments, controls, and outcome measurements.

2.8. Sensitivity analysis

We will also carry out a sensitivity analysis to check the robustness of merged outcome results by removing low quality studies.
2.9. Reporting bias

When there are at least 10 included RCTs, we will conduct Funnel plot\cite{34} and Egger’s regression test\cite{35} to identify any possible reporting bias.

2.10. Ethics and dissemination

No individual patient data will be involved in this study, thus, no ethic approval is needed. We will publish this study at a peer-reviewed journal.

3. Discussion

A numerous studies have reported that patients with KS can achieve encouraging benefits after ESWL treatment. However, their results are still not consistent. Although a recent associated systematic review has been published\cite{24}, there is still several high quality RCTs address this issue after that.\cite{25-32} Therefore, the purpose of this study is to update and to determine the effectiveness and safety of ESWL for patients with KS. This study may still have two limitations. First, some trials may have small sample size, which may affect results of this study. Second, the overall quality of some studies may be still low, which may impact study findings.

Author contributions

Conceptualization: Yong-chun Qiang, Yu-ge Guo, Yun-qi Wang.
Data curation: Yong-chun Qiang, Yu-ge Guo, Yun-qi Wang.
Formal analysis: Yong-chun Qiang.
Investigation: Yun-qi Wang.
Methodology: Yu-ge Guo.
Project administration: Yun-qi Wang.
Resources: Yong-chun Qiang, Yu-ge Guo.
Software: Yong-chun Qiang, Yu-ge Guo.
Supervision: Yun-qi Wang.
Validation: Yong-chun Qiang, Yu-ge Guo, Yun-qi Wang.
Visualization: Yong-chun Qiang, Yu-ge Guo, Yun-qi Wang.
Writing – original draft: Yong-chun Qiang, Yun-qi Wang.
Writing – review & editing: Yong-chun Qiang, Yu-ge Guo, Yun-qi Wang.
References

[1] Wang W, Fan J, Huang G, et al. Prevalence of kidney stones in mainland China: a systematic review. Sci Rep 2017;7:41630.

[2] Khan SR, Pearle MS, Robertson WG, et al. Kidney stones. Nat Rev Dis Primers 2016;2:16008.

[3] Xu H, Zisman AL, Coe FL, et al. Kidney stones: an update on current pharmacological management and future directions. Expert Opin Pharmacother 2013;14:435–47.

[4] Salhachea K, Maalouf NM, Sinnott B. Clinical review. Kidney stones 2012: pathogenesis, diagnosis, and management. J Clin Endocrinol Metab 2012;97:1847–60.

[5] Galvin DJ, Pearle MS. The contemporary management of renal and ureteric calculi. BJU Int 2006;98:1283–8.

[6] Patr JM, Desai D, Winkle D. Natural history and quality of life in patients with cystine urolithiasis: a single centre study. BJU Int 2015;116:31–5.

[7] Rao DS, Klerkender M, Littleton R, et al. Kidney stones 1983: a preventable cause of morbidity. Henry Ford Hosp Med J 1983;31:182–3.

[8] Donnelly CJ 3rd, Gupta A, Bensalah K, et al. Longitudinal evaluation of the SF-36 quality of life questionnaire in patients with kidney stones. Urol Res 2011;39:141–6.

[9] Bensalah K, Tuncel A, Gupta A, et al. Determinants of quality of life for patients with kidney stones. J Urol 2008;179:2238–43.

[10] Aune D, Mahamr-Saleh Y, Norat T, et al. Body fatness, diabetes, physical activity and risk of kidney stones: a systematic review and meta-analysis of cohort studies. Eur J Epidemiol 2018;33:1033–47.

[11] Yoshimura E, Sawada SS, Lee IM, et al. Body mass index and kidney stones: a cohort study of Japanese men. J Epidemiol 2016;26:131–6.

[12] Kirejczyk JK, Korzeniecka-Kozerska A, Baran M, et al. Dyslipidaemia in overweight children and adolescents is associated with an increased risk of kidney stones. Acta Paediatr 2015;104:e407–13.

[13] Domingos S, Serra A. Metabolic syndrome: a multifaceted risk factor for recurrent kidney stones. Scand J Urol 2014;48:414–9.

[14] Redmond EJ, Murphy CF, Leonard J, et al. The influence of dietary supplementation with cranberry tablets on the urinary risk factors for nephrolithiasis. World J Urol 2019;37:561–6.

[15] Lin E, Ho L, Lin MS, et al. Wu-Ling-San formula prophylaxis against recurrent calcium oxalate nephrolithiasis—a prospective randomized controlled trial. Afr J Tradit Complement Altern Med 2013;10:199–209.

[16] Hadzic J, Golka K, Selmski S, et al. Analgesia with acupuncture in extracorporeal shock wave lithotripsy of kidney stones-first results. Urology 2007;69:407–10.

[17] Byhagh SV, Pai KV, D’Souza MG. Effect of phenolic compounds from Bergenia ciliata (Haw.) Sternb leaves on Experimental kidney stones. Anc Sci Life 2010;30:14–7.

[18] Zhang B, Hu Y, Gao J, et al. Micropuncture versus extracorporeal intrarenal surgery for the management of moderately sized kidney stones: a systematic review and meta-analysis. Urol Int 2019;1:1–2.

[19] Ekici M, Ozgur BC, Senturk AR, et al. Efficacy and reliability of retrograde intrarenal surgery in treatment of pediatric kidney stones. Cureus 2018;10:e3719.

[20] Wilhelm K. Citrate salts for calcium containing kidney stones: prevention and treatment. Urologe A 2016;55:1487–90.

[21] Deem S, Defade B, Modak A, et al. Percutaneous nephrolithotomy versus extracorporeal shock wave lithotripsy for moderate sized kidney stones. Urology 2011;78:739–43.

[22] Menon M. Cost effectiveness of extracorporeal shock wave lithotripsy and percutaneous nephrolithotomy for medium-sized kidney stones: a randomised clinical trial. J Urol 1993;150:2 Pt 1:565.

[23] Carlson P, Kinn KC, Tiselius HG, et al. Cost effectiveness of extracorporeal shock wave lithotripsy and percutaneous nephrolithotomy for medium-sized kidney stones. A randomised clinical trial. Scand J Urol Nephrol 1992;26:257–63.

[24] Srivastava P, Potisar S, Lojanapirat B, et al. Extracorporeal shock wave lithotripsy (ESWL) versus percutaneous nephrolithotomy (PCNL) or retrograde intrarenal surgery (RIRS) for kidney stones. Cochrane Database Syst Rev 2014;CD007044.

[25] Nussberger F, Roth B, Metzger T, et al. A low or high BMI is a risk factor for renal hematoma after extracorporeal shock wave lithotripsy for kidney stones. Urolithiasis 2017;45:317–21.

[26] Ravier E, Abid N, Ruffon A, et al. Effectiveness of flexible ureteroscopy versus extracorporeal shock wave lithotripsy for kidney stones treatment. Prog Urol 2015;25:233–9.

[27] Vilches RM, Alaga A, Reyes D, et al. Comparison between retrograde intrarenal surgery and extracorporeal shock wave lithotripsy in the treatment of lower pole kidney stones up to 15mm. Prospective, randomized study. Actas Urol Esp 2015;39:236–42.

[28] Zeng GF, Li DD, Chen YF. Effect of extracorporeal shock wave lithotripsy on renal cortex in non-target areas of kidney stones in different parts. China Med Sci 2019;9:237–40.

[29] Jang DP, Zeng XH, Wang YZ. Observation of the clinical effect of extracorporeal shock wave lithotripsy in the treatment of kidney stones. World Latest Med Inform Abs 2019;19:42–3.

[30] Wang XT, Shen RL, Shao H, et al. Observation on the curative effect of extracorporeal shock wave lithotripsy on renal CT with different CT values. Zhejiang J Integr Tradit Chin Western Med 2019;29:208–10.

[31] Sun Q. The effect of extracorporeal shock wave lithotripsy on renal calculi on renal function indexes. China Minkang Med 2017;29:25–6.

[32] Zhao J, Xing SL. Observation of clinical efficacy of extracorporeal shock wave lithotripsy in treating urinary stones. Shaanxi Med J 2017;46:631–4.

[33] Mohr D, Shamsmeer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.

[34] Sutton AJ, Duval SJ, Tweedie RL, et al. Empirical assessment of effect of publication bias on meta-analyses. BMJ 2000;320:1574–7.

[35] Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34.